Article
Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase ( ALK )‐rearranged non‐small cell lung cancer
24 Aug 2019
Abstract excerpt
Abstract Anaplastic lymphoma kinase (ALK) fusions have been recognized as a therapeutic target in non‐small cell lung cancer (NSCLC). However, molecular signatures and clinical characteristics of the Chinese population with ALK‐rearranged NSCLC are not well elucidated. In the present study, we carried out targeted next‐generation sequencing on tissue and plasma ctDNA samples in 1688 patients with NSCLC. Overall,...
Topics
Join the communities discussing this publication.
